Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna Technology Center (MTC) in Norwood in the state of Massachusetts, in a move involving an investment of more than $140m.
Through this onshoring, the company will now operate complete end-to-end mRNA medicines manufacturing across the country.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is expected to strengthen Moderna’s network in the US, supporting commercial as well as clinical supply.
The initiative forms part of the company’s continued investment in US-based infrastructure, aimed at establishing a manufacturing platform to support its portfolio of mRNA therapies and vaccines.
Since partnering the US government through Operation Warp Speed, Moderna’s mRNA platform has led the way in biomedical innovation across autoimmune disorders, rare diseases, cancer and infectious diseases.
Moderna CEO Stéphane Bancel stated: “By onshoring drug product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community.”
Construction of the new facility has commenced, with completion targeted for the first half of 2027.
The investment will generate several skilled biomanufacturing jobs.
In 2025, Moderna received $590m in funding from the US Department of Health and Human Services (HHS) to expedite the development of mRNA-based pandemic influenza vaccines. The initiative was part of a broader effort to enhance the country’s preparedness for future infectious diseases.
